Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. GMRS
GMRS logo

GMRS Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
14.850
Open
14.370
VWAP
14.30
Vol
403.81K
Mkt Cap
791.27M
Low
13.920
Amount
5.77M
EV/EBITDA(TTM)
--
Total Shares
54.01M
EV
5.71B
EV/OCF(TTM)
--
P/S(TTM)
--
GMR Solutions Inc. is a provider of emergency medical services and integrated providers of essential alternate-site, out-of-hospital care in the United States and mobile clinical practice groups globally. It maintains longstanding relationships across the healthcare ecosystem, serving local communities, health systems, payors, public health and local, state and federal agencies. Its emergent care services include rapid, clinically appropriate responses, lifesaving critical interventions and, when necessary, transport to the next site of care. Its non-emergent care services include scheduled and non-emergency patient care. Together with its professional pilots, mechanics, communications specialists and other operational support roles, it delivers comprehensive care across a range of time-sensitive patient conditions, from cardiac arrests, strokes and significant traumatic injuries to acute behavioral health episodes, toxic exposures, and emergent in-the-field newborn deliveries.
Show More

Events Timeline

(ET)
2026-06-08
11:50:00
Quantum Computing Company Quantinuum Prices IPO at $60
select

News

NASDAQ.COM
8.5
06-11NASDAQ.COM
Biotech Companies See Significant Stock Gains
  • Parabilis Debut Performance: Parabilis Medicines Inc. saw its stock surge 58% on its Nasdaq debut, pricing 33.5 million shares at $20 each, with expected gross proceeds of approximately $670 million, indicating strong market demand for its innovative drug candidates.
  • Clover Health Legal Victory: Clover Health Investments Corp. achieved a legal victory against the U.S. Department of Health and Human Services, upgrading its PPO plan's star rating from 3.5 to 4.5, with projected total revenues for 2026 between $2.81 billion and $2.92 billion, reflecting a 49% year-over-year growth.
  • Shoulder Innovations Growth: Shoulder Innovations, Inc. reported a net revenue of $16.7 million for Q1, a 65% increase year-over-year, and expects full-year 2026 revenues between $65 million and $68 million, representing a growth of 37% to 44%, showcasing its strong position in the shoulder surgical market.
  • Myomo Stock Surge: Myomo Inc.'s stock rose over 17%, with projected Q2 2026 revenues between $10.3 million and $10.8 million, compared to $9.7 million in Q2 2025, reflecting increasing market demand for its wearable medical robotics products.
NASDAQ.COM
2.0
06-10NASDAQ.COM
Biotech Companies See Significant Stock Gains
  • Regentis Stock Surge: Regentis Biomaterials Ltd. shares soared over 88% as the company prepares to commence European Surgeon Training for GelrinC in Q3 2026, accelerating its commercialization efforts in knee cartilage repair and enhancing its competitive edge in the market.
  • Eloxx Uplisting Success: Eloxx Pharmaceuticals Inc. saw its stock rise more than 77% after uplisting to Nasdaq, with plans to issue 2.975 million shares at $11.00 each, expected to generate $66 million in revenue, supporting its clinical trials for Alport syndrome treatment.
  • Alignment Healthcare Gains: Alignment Healthcare Inc. shares increased over 25% following disclosures of RSU grants to executives, with projected Q2 2026 revenues between $1.295 billion and $1.315 billion, indicating strong growth potential in the healthcare sector.
  • Cartesian Strategic Licensing: Cartesian Therapeutics Inc. inked a strategic licensing deal with WestGene Biopharma to advance CAR-T therapies for autoimmune diseases, with a Phase 1 trial expected to start in 2H 2026, potentially driving innovation in this therapeutic area.
CNBC
6.0
06-08CNBC
Latest Wall Street Ratings Overview
  • BofA Upgrades Brown-Forman: Bank of America upgraded Brown-Forman from underperform to neutral, citing better-than-expected Q4/FY26 results and consistent sales delivery, indicating a more constructive outlook that could enhance market performance.
  • Goldman Sachs Upgrades W.R. Berkley: Goldman Sachs upgraded W.R. Berkley from neutral to buy, believing that sustainable underwriting activity will yield long-term benefits for investors, reflecting stability and growth potential in the insurance sector.
  • Morgan Stanley Initiates Cerebras: Morgan Stanley initiated coverage on Cerebras with an overweight rating, highlighting unique demand for low-latency inference solutions that is driving growth, with projected revenues of $6 billion by 2028 indicating a strong market outlook.
  • UBS Upgrades Cummins: UBS upgraded Cummins from neutral to buy and raised the price target to $850, anticipating double-digit growth in its power division and the rollout of new engines to drive earnings growth over the next two years.
renaissancecapital
8.5
06-02renaissancecapital
May IPO Market Rebounds with $11.5 Billion Raised
  • Record Fundraising: Thirteen IPOs raised a total of $11.5 billion in May, marking the highest monthly proceeds since November 2021, indicating a robust market recovery and renewed investor confidence.
  • Large Deals Dominate: AI chipmaker Cerebras led the market with a $5.6 billion deal, while geothermal energy developer Fervo and data center REIT Blackstone Digital Infrastructure Trust also raised over $1 billion each, highlighting strong demand in AI-related sectors.
  • Strong IPO Performance: Traditional IPOs averaged a 5% return from their offer prices, with about half closing above their issue prices, reflecting positive market sentiment towards new listings, particularly with Fervo and BXDC showing strong first-day gains.
  • Optimistic Future Outlook: With new filings from companies like SpaceX, more IPO transactions are expected in the coming months as the market broadens, and strong returns alongside a solid pipeline set the stage for a busy IPO calendar ahead.
seekingalpha
9.5
06-01seekingalpha
GMR Solutions Reports Q1 2026 Financial Results with Strong Guidance
  • Strong Financial Performance: GMR Solutions Inc. reported a Q1 2026 GAAP EPS of $0.28 with revenues of $1.46 billion, net income of $106.3 million, and adjusted EBITDA of $305.1 million, indicating robust growth in both revenue and profitability.
  • Strong Liquidity Position: As of March 31, 2026, the company maintained a liquidity position exceeding $1.1 billion, comprising $426.1 million in cash and cash equivalents and approximately $691.6 million in available borrowing capacity, ensuring financial flexibility for future investments and operations.
  • Preferred Stock Redemption: On March 6, 2026, GMR redeemed 189,050 shares of preferred stock for an aggregate redemption price of approximately $250 million, which not only optimizes the capital structure but may also enhance value for common shareholders.
  • 2026 Financial Guidance: The company established guidance for 2026, projecting net revenue between $5.89 billion and $6.18 billion, with adjusted EBITDA expected to range from $1.135 billion to $1.195 billion, reflecting confidence in future performance and positive market demand.
Newsfilter
9.5
06-01Newsfilter
GMR Solutions Reports Strong Q1 2026 Financial Results
  • Significant Revenue Growth: GMR Solutions reported net revenue of $1.4576 billion for Q1 2026, a 6.6% increase from $1.3674 billion in Q1 2025, indicating strong market demand in the emergency medical services sector and reinforcing its industry leadership.
  • Substantial Net Income Increase: The company achieved a net income of $106.3 million in Q1, up 179.7% year-over-year, reflecting GMR's success in cost control and operational efficiency, which enhances investor confidence in its long-term growth potential.
  • Adjusted EBITDA Improvement: Adjusted EBITDA reached $305.1 million, a 9.7% increase compared to $278.1 million in the previous year, demonstrating ongoing enhancements in profitability that could attract more investment and support future expansion plans.
  • Strong Liquidity Position: As of March 31, 2026, GMR maintained a liquidity position exceeding $1.1 billion, including $426.1 million in cash and cash equivalents, ensuring financial flexibility for future investments and operations.
Wall Street analysts forecast GMRS stock price to rise
0 Analyst Rating
Wall Street analysts forecast GMRS stock price to rise
0 Buy
0 Hold
0 Sell
Current: 0.000
sliders
Low
Averages
High
Current: 0.000
sliders
Low
Averages
High
No data

No data

Valuation Metrics

The current forward P/E ratio for GMR Solutions Inc (GMRS.N) is 0.00, compared to its 5-year average forward P/E of --. For a more detailed relative valuation and DCF analysis to assess GMR Solutions Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
Current PE
0.00
Overvalued PE
Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
4.68
Current EV/EBITDA
4.96
Overvalued EV/EBITDA
4.79
Undervalued EV/EBITDA
4.57

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.11
Current PS
0.12
Overvalued PS
0.12
Undervalued PS
0.10

Financials

AI Analysis
Annual
Quarterly

Whales Holding GMRS

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is GMR Solutions Inc (GMRS) stock price today?

The current price of GMRS is 14.12 USD — it has decreased -3.62

What is GMR Solutions Inc (GMRS)'s business?

GMR Solutions Inc. is a provider of emergency medical services and integrated providers of essential alternate-site, out-of-hospital care in the United States and mobile clinical practice groups globally. It maintains longstanding relationships across the healthcare ecosystem, serving local communities, health systems, payors, public health and local, state and federal agencies. Its emergent care services include rapid, clinically appropriate responses, lifesaving critical interventions and, when necessary, transport to the next site of care. Its non-emergent care services include scheduled and non-emergency patient care. Together with its professional pilots, mechanics, communications specialists and other operational support roles, it delivers comprehensive care across a range of time-sensitive patient conditions, from cardiac arrests, strokes and significant traumatic injuries to acute behavioral health episodes, toxic exposures, and emergent in-the-field newborn deliveries.

What is the price predicton of GMRS Stock?

Wall Street analysts forecast GMRS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMRS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is GMR Solutions Inc (GMRS)'s revenue for the last quarter?

GMR Solutions Inc revenue for the last quarter amounts to NaN USD, decreased

What is GMR Solutions Inc (GMRS)'s earnings per share (EPS) for the last quarter?

GMR Solutions Inc. EPS for the last quarter amounts to USD, decreased

How many employees does GMR Solutions Inc (GMRS). have?

GMR Solutions Inc (GMRS) has 0 emplpoyees as of June 27 2026.

What is GMR Solutions Inc (GMRS) market cap?

Today GMRS has the market capitalization of 791.27M USD.